AUS
NZ
UK
CA
USA
IND
Highlights
- ENDRA Life Sciences launches a clinical study for its TAEUS liver system in Germany.
- The study will evaluate TAEUS’ effectiveness in measuring liver fat against MRI-PDFF.
- The initiative supports broader adoption and regulatory approval efforts.
ENDRA Life Sciences (NASDAQ:NDRA), a company in the medical technology sector, has launched a clinical study for its TAEUS liver system at LMU University Hospital in Munich, Germany. The initiative marks a significant step in the company's efforts to establish its technology within the healthcare sector in Germany, the largest healthcare market in Europe. The focus of the study is to evaluate the performance of TAEUS, which is designed to measure liver fat, in comparison to the established MRI-PDFF test.
Clinical Study and its Objectives
The primary objective of this clinical study is to validate the capabilities of ENDRA’s TAEUS liver system. The device aims to measure liver fat levels, which is essential for diagnosing and managing liver conditions. By comparing the TAEUS system’s measurements with the MRI-PDFF, which is the current gold standard in liver fat assessment, the study seeks to confirm the accuracy and reliability of the technology.
Researchers at LMU University Hospital will conduct the study, gathering data that could play a pivotal role in demonstrating the clinical efficacy of the TAEUS system. The findings from this study are anticipated to be presented at medical congresses and published in peer-reviewed journals, further establishing ENDRA’s technology within the medical community.
Strategic Significance of the Study
This collaboration between ENDRA Life Sciences and LMU University Hospital is not only aimed at gathering clinical data but also at supporting ENDRA's ongoing regulatory efforts. The study is an important milestone as the company works toward an FDA De Novo submission, with the goal of securing regulatory approval for the TAEUS system. The results from this study are expected to provide critical evidence needed for the application process.
Moreover, this clinical trial serves as ENDRA’s strategic entry into Germany’s healthcare market. Germany represents one of the largest and most advanced healthcare markets in Europe, offering a valuable opportunity for the company to establish its technology on a broad scale. Success in this market could pave the way for further expansion across Europe and other international regions.
Implications for the Medical Technology Sector
The TAEUS liver system, with its potential to become a reliable and non-invasive method for liver fat measurement, offers a new approach within the medical technology sector. Unlike traditional imaging methods, TAEUS aims to provide clinicians with a portable, efficient, and cost-effective solution for assessing liver health, supporting the shift toward more accessible diagnostic tools.
This study is part of ENDRA’s strategy to expand its clinical data portfolio and promote the adoption of TAEUS technology as a trusted biomarker for liver fat measurement. As the company progresses with its initiatives, the integration of TAEUS into clinical settings may drive a shift in how liver conditions are managed and diagnosed, particularly in markets like Germany where healthcare technology adoption is advanced.
A Step Towards Broader Adoption
By collaborating with a prestigious institution like LMU University Hospital, ENDRA is taking a proactive approach to demonstrate the clinical utility of its technology. This step aligns with its mission to make the TAEUS system a standard in liver health diagnostics. The data gathered will not only support regulatory efforts but also serve as a foundation for introducing TAEUS to a wider audience, potentially increasing its acceptance and application in clinical environments.
